Hydroxocobalamin

The clinical depot form of Vitamin B12, providing prolonged tissue retention compared with cyanocobalamin. The standard injectable B12 form in European and UK pharmaceutical practice and the active substance in cyanide-poisoning antidote kits.

Dark red crystalline powder. Light-sensitive; requires opaque, sealed packaging. Pharmaceutical injectable doses typically 1 milligram per dose; cyanide-antidote kits use 5 grams per dose.

We supply pharmaceutical-grade and supplement-grade Hydroxocobalamin from manufacturers in China holding ISO, Halal, Kosher and other certifications relevant to the product and production.

Common market grades include Pharmaceutical Grade hydroxocobalamin acetate or chloride (≥ 98 percent, meeting BP/EP/USP specifications), Sterile API Grade for injectable formulations, and Supplement Grade for oral dosage forms.

Bulk and reduced-MOQ shipments. Batch-level COA covering assay, related cobalamins, water content, heavy metals, and microbiology.

Hydroxocobalamin is the natural circulating form of Vitamin B12 in human blood and tissues. The compound binds plasma proteins more tightly than cyanocobalamin, providing prolonged tissue retention and a depot effect that makes it the preferred injectable B12 form in many clinical traditions.

Industrial production proceeds by fermentation of Propionibacterium or Pseudomonas species to yield cyanocobalamin, followed by reductive displacement of the cyanide ligand under controlled conditions to yield the hydroxo form, which is then crystallized as the acetate or chloride salt.

Listed in BP, EP, USP, and JP pharmacopoeias. Approved by the U.S. FDA and EMA both as a B12 vitamin supplement and as the active substance in cyanide-poisoning antidote (Cyanokit). Listed on the WHO Model List of Essential Medicines for this antidote indication.

Strategic positioning combines two distinct applications with very different commercial dynamics: the steady volume of injectable B12 supplementation (the dominant prescribed B12 form in UK and EU healthcare) and the lower-volume but high-margin cyanide-antidote kit business (hospital emergency medicine and tactical first-aid kits).

The depot pharmacokinetic advantage of hydroxocobalamin permits less frequent injection schedules (typically once every 3 months for maintenance) compared with cyanocobalamin, making it the preferred choice for long-term parenteral B12 maintenance in pernicious anemia.

• Pharmaceutical injectable preparations: the standard B12 injection in UK and EU clinical practice
• Cyanide-poisoning antidote kits (5 g IV dose, hospital emergency medicine)
• Dietary supplements: depot-form B12 for pernicious anemia and malabsorption management
• Multi-form active-B12 blends
• Clinical nutrition for B12 deficiency
• Veterinary injectable preparations
• Functional medicine sublingual and oral applications
• Specialty pharmaceutical formulations